Left ventricular (LV) dysfunction c-kit-positive, lineage-negative cardiac stem cells (CSC) improving post-infarction when given to animals. We conducted an experiment phase 1 (Stem Cell Infusion in Patients with ischemic cardiomyopathy [Scipio]) from autologous CSC for the treatment of heart failure due to ischemic heart disease.In trial stage A Scipio, patients with post-infarction LV dysfunction (ejection fraction [EF] ≤ 40%) prior to coronary artery bypass grafting were consecutively enrolled in the treatment and control groups. In stage B, patients were randomly assigned to treatment or control groups in a ratio of 2: 3 by using the block scheme of computer-generated randomization. 1 million autologous CSC given by intracoronary infusion at an average of 113 days (SE 4) after surgery; untreated controls.
Although this study is an open label, echocardiographic analysis did not know the duties of the group. The primary endpoint was a short-term security of CSC and the secondary endpoint was efficacy. A per-protocol analysis were used. This study is registered with ClinicalTrials.gov, number NCT00474461.This study is still in progress. 16 patients were assigned to the treatment group and seven for the control group; no side effects were reported related CSC.
On 14 CSC-treated patients were analyzed, LVEF increased from 30 · 3% (SE 1 · 9) before CSC infusion to 38 · 5% (2 · 8) at 4 months after infusion (p = 0 · 001). In contrast, the seven control patients, as long as the appropriate time interval, LVEF did not change (30 · 1% [2 · 4] at 4 months after CABG vs 30 · 2% [2 · 5] at 8 months after CABG). Importantly, CSC healthful effects are even more pronounced in the first year in eight patients (eg, LVEF increased by 12 · 3 unit ejection fraction [2 · 1] vs baseline, p = 0 · 0007).
In seven patients treated in whom cardiac MRI can be done, infarct size decreased from 32 · 6 g (6 · 3) by 7 · 8 g (1 · 7; 24%) at 4 months (p = 0 · 004) and 9 · 8 g (3 · 5; 30%) at 1 year (p = 0 · 04) .This preliminary results in patients with very encouraging. They suggest that intracoronary infusion of autologous CSC effective in improving LV systolic function and reduced infarct size in patients with heart failure after myocardial infarction, and warrant further, larger, phase 2 studies.University of Louisville Research Foundation and the National Institutes of Health ,
 D-Luciferin, Sodium Salt |
|||
| 7902-25G | Biovision | Ask for price | |
D-Luciferin, Sodium Salt |
|||
| 7902-3PK | Biovision | EUR 925 | |
D-Luciferin, Sodium Salt |
|||
| 7902-50G | Biovision | Ask for price | |
D-Luciferin, Sodium Salt |
|||
| 7902-5PK | Biovision | EUR 1496 | |
 D-Luciferin, sodium salt |
|||
| 10102 | Biotium | 10MG | EUR 123 |
|
Description: Minimum order quantity: 1 unit of 10MG |
|||
D-Luciferin, sodium salt |
|||
| 10102-1 | Biotium | 50MG | EUR 245 |
|
Description: Minimum order quantity: 1 unit of 50MG |
|||
D-Luciferin, sodium salt |
|||
| 10102-2 | Biotium | 1G | EUR 714 |
|
Description: Minimum order quantity: 1 unit of 1G |
|||
) D-Luciferin (sodium salt) |
|||
| HY-12591 | MedChemExpress | 50mg | EUR 153 |
 D-Luciferin sodium salt |
|||
| B8311-10 | ApexBio | 10 mg | EUR 131 |
D-Luciferin sodium salt |
|||
| B8311-200 | ApexBio | 200 mg | EUR 699 |
D-Luciferin sodium salt |
|||
| B8311-50 | ApexBio | 50 mg | EUR 293 |
 D-Luciferin, Potassium Salt |
|||
| 7903-100 | Biovision | EUR 120 | |
D-Luciferin, Potassium Salt |
|||
| 7903-10G | Biovision | EUR 2409 | |
D-Luciferin, Potassium Salt |
|||
| 7903-10PK | Biovision | EUR 2763 | |
D-Luciferin, Potassium Salt |
|||
| 7903-1G | Biovision | EUR 354 | |
D-Luciferin, Potassium Salt |
|||
| 7903-25G | Biovision | Ask for price | |
D-Luciferin, Potassium Salt |
|||
| 7903-3PK | Biovision | EUR 925 | |
D-Luciferin, Potassium Salt |
|||
| 7903-50G | Biovision | Ask for price | |
D-Luciferin, Potassium Salt |
|||
| 7903-5PK | Biovision | EUR 1496 | |
 D-Luciferin, potassium salt |
|||
| 10101 | Biotium | 10MG | EUR 112 |
|
Description: Minimum order quantity: 1 unit of 10MG |
|||
D-Luciferin, potassium salt |
|||
| 10101-1 | Biotium | 50MG | EUR 234 |
|
Description: Minimum order quantity: 1 unit of 50MG |
|||
D-Luciferin, potassium salt |
|||
| 10101-2 | Biotium | 1G | EUR 714 |
|
Description: Minimum order quantity: 1 unit of 1G |
|||
D-Luciferin, Potassium Salt |
|||
| D0510-010 | GenDepot | 100mg | EUR 185 |
D-Luciferin, Potassium Salt |
|||
| D0510-050 | GenDepot | 500mg | EUR 504 |
D-Luciferin, Potassium Salt |
|||
| D0510-100 | GenDepot | 1g | EUR 847 |
 D-Luciferin potassium salt |
|||
| HY-12591B | MedChemExpress | 50mg | EUR 153 |
 D-Luciferin, sodium salt *CAS#: 103404-75-7* |
|||
| 12509 | AAT Bioquest | 25 mg | EUR 115 |
D-Luciferin, sodium salt *CAS#: 103404-75-7* |
|||
| 12510 | AAT Bioquest | 100 mg | EUR 132 |
D-Luciferin, sodium salt *CAS#: 103404-75-7* |
|||
| 12511 | AAT Bioquest | 1 g | EUR 528 |
 EZSolution? D-Luciferin, Potassium Salt |
|||
| B3001-set | Biovision | EUR 370 | |
 Brite-Light? D-Luciferin, Potassium Salt |
|||
| B3000-10PK | Biovision | EUR 2268 | |
Brite-Light? D-Luciferin, Potassium Salt |
|||
| B3000-1G | Biovision | EUR 327 | |
Brite-Light? D-Luciferin, Potassium Salt |
|||
| B3000-5PK | Biovision | EUR 1300 | |
 D-Luciferin |
|||
| GP9319-100MG | Glentham Life Sciences | 100 mg | EUR 221 |
D-Luciferin |
|||
| GP9319-10MG | Glentham Life Sciences | 10 mg | EUR 70 |
D-Luciferin |
|||
| GP9319-25MG | Glentham Life Sciences | 25 mg | EUR 110 |
D-Luciferin |
|||
| GP9319-50MG | Glentham Life Sciences | 50 mg | EUR 150 |
D-Luciferin |
|||
| HY-12591A | MedChemExpress | 10mg | EUR 108 |
D-Luciferin |
|||
| B6040-10 | ApexBio | 10 mg | EUR 131 |
|
Description: D-luciferin is a cell-permeable chemiluminescent luciferase substrate with a Km of approximately 2 ?M. D-luciferin could emit lights upon oxidative decarboxylation in the presence of ATP. |
|||
D-Luciferin |
|||
| B6040-200 | ApexBio | 200 mg | EUR 699 |
|
Description: D-luciferin is a cell-permeable chemiluminescent luciferase substrate with a Km of approximately 2 ?M. D-luciferin could emit lights upon oxidative decarboxylation in the presence of ATP. |
|||
D-Luciferin |
|||
| B6040-50 | ApexBio | 50 mg | EUR 293 |
|
Description: D-luciferin is a cell-permeable chemiluminescent luciferase substrate with a Km of approximately 2 ?M. D-luciferin could emit lights upon oxidative decarboxylation in the presence of ATP. |
|||
 D-Luciferin, potassium salt *CAS#: 115144-35-9* |
|||
| 12505 | AAT Bioquest | 25 mg | EUR 115 |
D-Luciferin, potassium salt *CAS#: 115144-35-9* |
|||
| 12506 | AAT Bioquest | 100 mg | EUR 132 |
D-Luciferin, potassium salt *CAS#: 115144-35-9* |
|||
| 12507 | AAT Bioquest | 1 g | EUR 263 |
 D-Luciferin acetate |
|||
| 12516 | AAT Bioquest | 5 mg | EUR 219 |
 Methyl beta-D-glucuronide sodium salt |
|||
| GC4190-1G | Glentham Life Sciences | 1 g | EUR 229 |
Methyl beta-D-glucuronide sodium salt |
|||
| GC4190-250MG | Glentham Life Sciences | 250 mg | EUR 110 |
 D-Glucuronic acid sodium salt monohydrate |
|||
| GC8431-100G | Glentham Life Sciences | 100 g | EUR 126 |
D-Glucuronic acid sodium salt monohydrate |
|||
| GC8431-250G | Glentham Life Sciences | 250 g | EUR 229 |
D-Glucuronic acid sodium salt monohydrate |
|||
| GC8431-25G | Glentham Life Sciences | 25 g | EUR 70 |
D-Glucuronic acid sodium salt monohydrate |
|||
| GC8431-5G | Glentham Life Sciences | 5 g | EUR 46 |
 D-Glucosamine 2-sulfate sodium salt |
|||
| GC9126-25MG | Glentham Life Sciences | 25 mg | EUR 61 |
 D-Glucuronic acid, sodium salt, monohydrate |
|||
| GB0483 | Bio Basic | 5g | EUR 107.42 |
 (sodium salt)) Estradiol 17-(?-D-Glucuronide) (sodium salt) |
|||
| C3840-5 | ApexBio | 5 mg | EUR 132 |
|
Description: Km: 75 ?MEstradiol 17-(?-D-Glucuronide) is a substrate of the multidrug resistance protein 2 (MRP2).MRP2 is a member of the superfamily of ATP-binding cassette (ABC) transporters, which transport various molecules across extra- and intra-cellular membranes. |
|||
Estradiol 17-(?-D-Glucuronide) (sodium salt) |
|||
| C3840-10 | ApexBio | 10 mg | EUR 206 |
|
Description: Km: 75 ?MEstradiol 17-(?-D-Glucuronide) is a substrate of the multidrug resistance protein 2 (MRP2).MRP2 is a member of the superfamily of ATP-binding cassette (ABC) transporters, which transport various molecules across extra- and intra-cellular membranes. |
|||
Estradiol 17-(?-D-Glucuronide) (sodium salt) |
|||
| C3840-25 | ApexBio | 25 mg | EUR 338 |
|
Description: Km: 75 ?MEstradiol 17-(?-D-Glucuronide) is a substrate of the multidrug resistance protein 2 (MRP2).MRP2 is a member of the superfamily of ATP-binding cassette (ABC) transporters, which transport various molecules across extra- and intra-cellular membranes. |
|||
Estradiol 17-(?-D-Glucuronide) (sodium salt) |
|||
| C3840-50 | ApexBio | 50 mg | EUR 502 |
|
Description: Km: 75 ?MEstradiol 17-(?-D-Glucuronide) is a substrate of the multidrug resistance protein 2 (MRP2).MRP2 is a member of the superfamily of ATP-binding cassette (ABC) transporters, which transport various molecules across extra- and intra-cellular membranes. |
|||
 (sodium salt)) Estradiol 3-(?-D-Glucuronide) (sodium salt) |
|||
| C3897-1 | ApexBio | 1 mg | EUR 118 |
|
Description: ?-estradiol 3-(?-d-glucuronide) (E23G) is a noncholestatic regioisomer of the estrogen metabolite, E217G (?-Estradiol 17-(?-d-glucuronide)) [1]. E23G functions as a substrate for multidrug resistance associated protein 2 (MRP2) [2]. |
|||
Estradiol 3-(?-D-Glucuronide) (sodium salt) |
|||
| C3897-10 | ApexBio | 10 mg | EUR 527 |
|
Description: ?-estradiol 3-(?-d-glucuronide) (E23G) is a noncholestatic regioisomer of the estrogen metabolite, E217G (?-Estradiol 17-(?-d-glucuronide)) [1]. E23G functions as a substrate for multidrug resistance associated protein 2 (MRP2) [2]. |
|||
Estradiol 3-(?-D-Glucuronide) (sodium salt) |
|||
| C3897-25 | ApexBio | 25 mg | EUR 1073 |
|
Description: ?-estradiol 3-(?-d-glucuronide) (E23G) is a noncholestatic regioisomer of the estrogen metabolite, E217G (?-Estradiol 17-(?-d-glucuronide)) [1]. E23G functions as a substrate for multidrug resistance associated protein 2 (MRP2) [2]. |
|||
Estradiol 3-(?-D-Glucuronide) (sodium salt) |
|||
| C3897-5 | ApexBio | 5 mg | EUR 306 |
|
Description: ?-estradiol 3-(?-d-glucuronide) (E23G) is a noncholestatic regioisomer of the estrogen metabolite, E217G (?-Estradiol 17-(?-d-glucuronide)) [1]. E23G functions as a substrate for multidrug resistance associated protein 2 (MRP2) [2]. |
|||
) D-Luciferin (Free acid) |
|||
| 2779-1000 | Biovision | EUR 338 | |
D-Luciferin (Free acid) |
|||
| 2779-250 | Biovision | EUR 175 | |
D-Luciferin (Free acid) |
|||
| 2779-500 | Biovision | EUR 251 | |
D-Luciferin (Free acid) |
|||
| 2779-5000 | Biovision | EUR 1273 | |
 D-Luciferin, free acid |
|||
| 10100 | Biotium | 10MG | EUR 112 |
|
Description: Minimum order quantity: 1 unit of 10MG |
|||
D-Luciferin, free acid |
|||
| 10100-1 | Biotium | 50MG | EUR 234 |
|
Description: Minimum order quantity: 1 unit of 50MG |
|||
D-Luciferin, free acid |
|||
| 10100-2 | Biotium | 1G | EUR 714 |
|
Description: Minimum order quantity: 1 unit of 1G |
|||
) DMNPE-Caged D-Luciferin: (5mg) |
|||
| 10103 | Biotium | 5MG | EUR 148 |
|
Description: Minimum order quantity: 1 unit of 5MG |
|||
 D-Luciferin-6-O-beta-D-galactopyranoside |
|||
| B1802-25 | Biovision | EUR 892 | |
D-Luciferin-6-O-beta-D-galactopyranoside |
|||
| B1802-5 | Biovision | EUR 262 | |
 Hepes, Sodium Salt |
|||
| CH039 | ABM | 25 g | EUR 118 |
Hepes, Sodium Salt |
|||
| CH040 | ABM | 100 g | EUR 169 |
Hepes, Sodium Salt |
|||
| CH041 | ABM | 500 g | EUR 374 |
 Ampicillin Sodium Salt |
|||
| AK0839-0010 | Akron Biotech | 10g | Ask for price |
Ampicillin Sodium Salt |
|||
| AK0839-0025 | Akron Biotech | 25g | Ask for price |
Ampicillin Sodium Salt |
|||
| AK0839-0100 | Akron Biotech | 100g | Ask for price |
 Heparin Sodium Salt |
|||
| AK3004-1000 | Akron Biotech | 1g | Ask for price |
Heparin Sodium Salt |
|||
| AK3004-5000 | Akron Biotech | 5g | Ask for price |
) Thyroxine (Sodium salt) |
|||
| 30-AT52 | Fitzgerald | 1 gram | EUR 352 |
|
Description: High purity Thyroxine sodium salt |
|||
) Triiodothyronine (Sodium salt) |
|||
| 30-AT53 | Fitzgerald | 1 gram | EUR 849 |
|
Description: High purity (>99%) Triiodothyronine sodium salt |
|||
 Nigericin sodium salt |
|||
| 2096-25 | Biovision | EUR 387 | |
Nigericin sodium salt |
|||
| 2096-5 | Biovision | EUR 147 | |
 NADP, sodium salt |
|||
| 2737-100 | Biovision | EUR 153 | |
NADP, sodium salt |
|||
| 2737-1000 | Biovision | EUR 784 | |
NADP, sodium salt |
|||
| 2737-500 | Biovision | EUR 457 | |
 Novobiocin Sodium Salt |
|||
| B1526-1G | Biovision | EUR 109 | |
Novobiocin Sodium Salt |
|||
| B1526-5G | Biovision | EUR 240 | |
 Cefazolin Sodium Salt |
|||
| B1530-1G | Biovision | EUR 142 | |
Cefazolin Sodium Salt |
|||
| B1530-5G | Biovision | EUR 359 | |
 Cefoxitin Sodium Salt |
|||
| B1892-1G | Biovision | EUR 185 | |
Cefoxitin Sodium Salt |
|||
| B1892-500 | Biovision | EUR 131 | |
Cefoxitin Sodium Salt |
|||
| B1892-5G | Biovision | EUR 577 | |
 Cefotaxime Sodium Salt |
|||
| abx188641-100g | Abbexa | 100 g | EUR 509 |
 Tianeptine Sodium Salt |
|||
| abx188914-25g | Abbexa | 25 g | EUR 314 |
 CAPS, sodium salt |
|||
| CB0097 | Bio Basic | 50g | EUR 71.75 |
 CAPSO, sodium salt |
|||
| CD0041 | Bio Basic | 50g | EUR 76.1 |
 Cefamandole sodium salt |
|||
| C079-100MG | TOKU-E | 100 mg | EUR 148 |
Cefamandole sodium salt |
|||
| C079-500MG | TOKU-E | 500 mg | EUR 474 |
 Resazurin, sodium salt |
|||
| 10054 | Biotium | 10MG | EUR 148 |
|
Description: Minimum order quantity: 1 unit of 10MG |
|||
Cefotaxime Sodium Salt |
|||
| 20-abx082178 | Abbexa |
|
|
 PIPES Sodium Salt |
|||
| 20-abx082438 | Abbexa |
|
|
 Carboxymethylcellulose sodium salt |
|||
| abx082467-100g | Abbexa | 100 g | EUR 189 |
Ampicillin Sodium Salt |
|||
| abx082587-5g | Abbexa | 5 g | EUR 175 |
 TAPS, sodium salt |
|||
| TB0920 | Bio Basic | 50g | EUR 71.75 |
 TAPSO, sodium salt |
|||
| TB0922 | Bio Basic | 50g | EUR 102.2 |
 MES sodium salt |
|||
| GB1926-10G | Glentham Life Sciences | 10 g | EUR 50 |
MES sodium salt |
|||
| GB1926-250G | Glentham Life Sciences | 250 g | EUR 181 |
MES sodium salt |
|||
| GB1926-500G | Glentham Life Sciences | 500 g | EUR 298 |
 MOPSO sodium salt |
|||
| GB3228-100G | Glentham Life Sciences | 100 g | EUR 94 |
MOPSO sodium salt |
|||
| GB3228-25G | Glentham Life Sciences | 25 g | EUR 58 |
MOPSO sodium salt |
|||
| GB3228-500G | Glentham Life Sciences | 500 g | EUR 229 |
 TES sodium salt |
|||
| GB4016-100G | Glentham Life Sciences | 100 g | EUR 150 |
TES sodium salt |
|||
| GB4016-500G | Glentham Life Sciences | 500 g | EUR 429 |
 CAPSO sodium salt |
|||
| GB4515-100G | Glentham Life Sciences | 100 g | EUR 110 |
CAPSO sodium salt |
|||
| GB4515-25G | Glentham Life Sciences | 25 g | EUR 54 |
CAPSO sodium salt |
|||
| GB4515-500G | Glentham Life Sciences | 500 g | EUR 309 |
 MOPS sodium salt |
|||
| GB8397-100G | Glentham Life Sciences | 100 g | EUR 66 |
MOPS sodium salt |
|||
| GB8397-1KG | Glentham Life Sciences | 1 kg | EUR 257 |
 DIPSO sodium salt |
|||
| GB8985-250G | Glentham Life Sciences | 250 g | EUR 628 |
 BES sodium salt |
|||
| GB9133-25G | Glentham Life Sciences | 25 g | EUR 86 |
 HEPES sodium salt |
|||
| GB9181-250G | Glentham Life Sciences | 250 g | EUR 99 |
HEPES sodium salt |
|||
| GB9181-500G | Glentham Life Sciences | 500 g | EUR 150 |
 Heparin sodium salt |
|||
| GC2310-100MG | Glentham Life Sciences | 100 mg | EUR 46 |
Heparin sodium salt |
|||
| GC2310-1G | Glentham Life Sciences | 1 g | EUR 82 |
Heparin sodium salt |
|||
| GC2310-250MG | Glentham Life Sciences | 250 mg | EUR 54 |
 XTT sodium salt |
|||
| GC5281-100MG | Glentham Life Sciences | 100 mg | EUR 205 |
XTT sodium salt |
|||
| GC5281-250MG | Glentham Life Sciences | 250 mg | EUR 325 |
XTT sodium salt |
|||
| GC5281-25MG | Glentham Life Sciences | 25 mg | EUR 94 |
XTT sodium salt |
|||
| GC5281-50MG | Glentham Life Sciences | 50 mg | EUR 142 |
 Casein sodium salt |
|||
| GE5861-100G | Glentham Life Sciences | 100 g | EUR 43 |
Casein sodium salt |
|||
| GE5861-1KG | Glentham Life Sciences | 1 kg | EUR 70 |
Casein sodium salt |
|||
| GE5861-250G | Glentham Life Sciences | 250 g | EUR 47 |
Casein sodium salt |
|||
| GE5861-500G | Glentham Life Sciences | 500 g | EUR 54 |
 TAPS sodium salt |
|||
| GB0912-100G | Glentham Life Sciences | 100 g | EUR 134 |
TAPS sodium salt |
|||
| GB0912-25G | Glentham Life Sciences | 25 g | EUR 62 |
TAPS sodium salt |
|||
| GB0912-500G | Glentham Life Sciences | 500 g | EUR 341 |
 TAPSO sodium salt |
|||
| GB1759-100G | Glentham Life Sciences | 100 g | EUR 134 |
TAPSO sodium salt |
|||
| GB1759-25G | Glentham Life Sciences | 25 g | EUR 62 |
MES sodium salt |
|||
| GB1926-100G | Glentham Life Sciences | 100 g | EUR 110 |
MES sodium salt |
|||
| GB1926-25G | Glentham Life Sciences | 25 g | EUR 62 |
MOPSO sodium salt |
|||
| GB3228-250G | Glentham Life Sciences | 250 g | EUR 150 |
TES sodium salt |
|||
| GB4016-250G | Glentham Life Sciences | 250 g | EUR 269 |
TES sodium salt |
|||
| GB4016-25G | Glentham Life Sciences | 25 g | EUR 70 |
CAPSO sodium salt |
|||
| GB4515-250G | Glentham Life Sciences | 250 g | EUR 205 |
MOPS sodium salt |
|||
| GB8397-250G | Glentham Life Sciences | 250 g | EUR 104 |
MOPS sodium salt |
|||
| GB8397-25G | Glentham Life Sciences | 25 g | EUR 49 |
MOPS sodium salt |
|||
| GB8397-500G | Glentham Life Sciences | 500 g | EUR 161 |
DIPSO sodium salt |
|||
| GB8985-100G | Glentham Life Sciences | 100 g | EUR 329 |
DIPSO sodium salt |
|||
| GB8985-25G | Glentham Life Sciences | 25 g | EUR 150 |
BES sodium salt |
|||
| GB9133-100G | Glentham Life Sciences | 100 g | EUR 181 |
BES sodium salt |
|||
| GB9133-250G | Glentham Life Sciences | 250 g | EUR 341 |
HEPES sodium salt |
|||
| GB9181-100G | Glentham Life Sciences | 100 g | EUR 70 |
HEPES sodium salt |
|||
| GB9181-1KG | Glentham Life Sciences | 1 kg | EUR 229 |
HEPES sodium salt |
|||
| GB9181-25G | Glentham Life Sciences | 25 g | EUR 54 |